TScan Therapeutics, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| TCRX | INAB | MRKR | GDTC | CLLS | ALLO | |
|---|---|---|---|---|---|---|
| Market cap | 14.23M | 9.18M | 16.84M | 10.61M | 117.86M | 411.13M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -0.4 | -1.0 | -1.9 | -5.9 | -1.9 | -1.9 |
| Price/book | 0.2 | 0.5 | 1.4 | 2.7 | 2.1 | 0.9 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −83.35% | −41.72% | +6.52% | −56.87% | −66.56% | +0.90% |
| Today | +11.11% | −2.02% | +2.76% | −2.31% | +7.34% | +6.25% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All TCRX news ›TScan Therapeutics, Inc. (NASDAQ:TCRX) Stock Has Average Price Target of $2.67
Posted by Mitch Edgeman on Nov 3rd, 2026 Read Our Latest Research Report on TScan Therapeutics TScan Therapeutics, Inc is a clinical-stage biotechnology company developing T cell receptor-engineered T cell (TCR-T) therapies for cancer. Its…
TScan Therapeutics (NASDAQ:TCRX) versus Altimmune (NASDAQ:ALT) Head-To-Head Contrast
Posted by Defense World Staff on Oct 25th, 2026 TScan Therapeutics (NASDAQ:TCRX – Get Free Report) and Altimmune (NASDAQ:ALT – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare…
Alnylam Pharmaceuticals (NASDAQ:ALNY) and TScan Therapeutics (NASDAQ:TCRX) Critical Survey
Posted by Danessa Lincoln on Oct 20th, 2026 TScan Therapeutics (NASDAQ:TCRX – Get Free Report) and Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) are both healthcare companies, but which is the better stock? We will compare the…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- themarketsdaily.com2
- defenseworld.net1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 3 articles, not a forecast.